Skip to main content

Mereo BioPharma Group PLC (MREO)

NASDAQ: MREO · IEX Real-Time Price · USD
2.73
+0.09 (3.41%)
After-hours:Sep 17, 2021 6:51 PM EDT
2.64
0.02 (0.76%)
At close: Sep 17, 4:00 PM
Market Cap287.50M
Revenue (ttm)n/a
Net Income (ttm)-224.15M
Shares Out108.90M
EPS (ttm)-3.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume618,973
Open2.60
Previous Close2.62
Day's Range2.59 - 2.67
52-Week Range1.90 - 4.71
Beta1.49
AnalystsStrong Buy
Price Target8.00 (+202.9%)
Est. Earnings DateSep 21, 2021

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197...

IndustryBiotechnology
Founded2015
CEODenise Pollard-Knight
Employees38
Stock ExchangeNASDAQ
Ticker SymbolMREO
Full Company Profile

Financial Performance

Financial numbers in millions GBPFinancial Statements

Analyst Forecast

According to one analyst, the rating for MREO stock is "Strong Buy" and the 12-month stock price forecast is 8.00.

Price Target
$8.00
(202.94% upside)
Analyst Consensus: Strong Buy

News

Mereo's Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome

Mereo BioPharma Group plc (NASDAQ: MREO) has announced data from an interim analysis of an investigator-initiated study of alvelestat, in patients with Bronchiolitis Obliterans Syndrome (BOS), following...

3 months ago - Benzinga

Cancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab

Cancer Focus Fund LP, established in collaboration with The University of Texas MD Anderson Cancer Center and Mereo BioPharma Group plc (NASDAQ: MREO), has entered into a funding agreement. The partners...

4 months ago - Benzinga

Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference

LONDON and REDWOOD City, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology an...

5 months ago - GlobeNewsWire

Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights

-- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta ---- Further Strengthened Management Team ---- OncXerna Global Licensing Agreement for Navicixizumab ---- Stre...

5 months ago - GlobeNewsWire

Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference

LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

7 months ago - GlobeNewsWire

Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Und...

LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

7 months ago - GlobeNewsWire

Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares

LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

7 months ago - GlobeNewsWire

Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares

LONDON and REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

7 months ago - GlobeNewsWire

7 Penny Stocks on a Tear Right Now and Still Worth Buying

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

8 months ago - InvestorPlace

Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise

9 months ago - GlobeNewsWire

Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on ...

LONDON and REDWOOD CITY, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

9 months ago - GlobeNewsWire

Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development

LONDON and REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

9 months ago - GlobeNewsWire

Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020

LONDON and REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

10 months ago - GlobeNewsWire

Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference

LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

10 months ago - GlobeNewsWire

Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regula...

LONDON and REDWOOD CITY, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

10 months ago - GlobeNewsWire

Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020

11 months ago - GlobeNewsWire

Mereo BioPharma's (MREO) CEO Denise Scots-Knight on 2020 Interim Financial Results Conference Call Transcript

Mereo BioPharma's (MREO) CEO Denise Scots-Knight on 2020 Interim Financial Results Conference Call Transcript

11 months ago - Seeking Alpha

Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update

On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020

11 months ago - GlobeNewsWire

Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Impe...

LONDON and REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on ...

11 months ago - GlobeNewsWire

Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2020 and Host Conference Call...

LONDON and REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on ...

1 year ago - GlobeNewsWire

Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Resp...

LONDON and REDWOOD CITY, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on o...

1 year ago - GlobeNewsWire

Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, ...

LONDON and REDWOOD CITY, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on o...

1 year ago - GlobeNewsWire

Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019

Operational progress, positioned for clinical milestones in oncology and rare diseases Operational progress, positioned for clinical milestones in oncology and rare diseases

1 year ago - GlobeNewsWire

Mereo BioPharma Announces Completion of $70 Million Private Placement

Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio

1 year ago - GlobeNewsWire

Business Update and Directorate Change

LONDON and REDWOOD CITY, Calif., March 27, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on r...

1 year ago - GlobeNewsWire